These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review].
    Author: Tajti J, Csáti A, Szok D.
    Journal: Ideggyogy Sz; 2023 Sep 30; 76(9-10):293-296. PubMed ID: 37782065.
    Abstract:
    <p>Migraine as a common primary headache disorder has a significant negative effect on quality of life of the patients. Its pharmacotreatment includes acute and preventative therapies. Based on the shared therapeutic guideline of the European Headache Federation and the European Academy of Neurology for acute migraine treatment a combination of triptans and non-steroidal anti-inflammatory drugs is recommended for acute migraine treatment in triptan-nonresponders. In this short review we summarized the results of the randomized controlled clinical trials evaluating the effectiveness and safety of sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination. It was revealed that the fix-dose combination was better than placebo for the primary outcomes of exemption of pain and headache relief at 2 hours. Furthermore the combination showed beneficial effect on accompanying symptoms of migraine attack (i.e. nausea, photo- and phonophobia). Adverse events were mild or moderate in severity and rarely led to withdrawal of the drug.<br>It can be concluded that sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination is effective, safe and well-tolerated in the acute treatment of migraine.&nbsp;</p>. <p>A migr&eacute;n az elsődleges fejf&aacute;j&aacute;sbetegs&eacute;gek k&ouml;z&eacute; tartoz&oacute; gyakori megbeteged&eacute;s, ami nagym&eacute;rt&eacute;kben k&aacute;rosítja az egy&eacute;n &eacute;letminős&eacute;g&eacute;t. Gy&oacute;gyszeres kezel&eacute;s&eacute;ben akut &eacute;s megelőző ter&aacute;pi&aacute;kat k&uuml;l&ouml;nít&uuml;nk el. Az Eur&oacute;pai Fejf&aacute;j&aacute;s T&aacute;rsas&aacute;g &eacute;s az Eur&oacute;pai Neu&shy;rol&oacute;giai Akad&eacute;mia k&ouml;z&ouml;s ter&aacute;pi&aacute;s aj&aacute;nl&aacute;sa alapj&aacute;n rohamter&aacute;pi&aacute;ban nem kiel&eacute;gítő tript&aacute;nv&aacute;lasz eset&eacute;n javasolt tript&aacute;n &eacute;s nem szteroid gyullad&aacute;sg&aacute;tl&oacute;k egy&uuml;ttes ad&aacute;sa.&nbsp;<br>Munk&aacute;nkban a fix d&oacute;zis&uacute; szumatript&aacute;n&ndash;naprox&eacute;n-n&aacute;trium (85 mg/500 mg) kombin&aacute;ci&oacute;j&uacute; tabletta haszn&aacute;lat&aacute;val kapcsolatos eredm&eacute;nyeket (hat&aacute;soss&aacute;g, biztons&aacute;goss&aacute;g) tekintj&uuml;k &aacute;t randomiz&aacute;lt klinikai vizsg&aacute;latok eredm&eacute;nyei alapj&aacute;n. A fix d&oacute;zis&uacute; szumatript&aacute;n&ndash;naprox&eacute;n-n&aacute;trium kombin&aacute;lt farmakon a placeb&oacute;hoz &eacute;s az egyes &ouml;sszetevőkh&ouml;z viszonyítva statisztikailag szignifik&aacute;nsan t&ouml;bb migr&eacute;nes p&aacute;ciensben eredm&eacute;nyezett a gy&oacute;gyszerbev&eacute;telt k&ouml;vetően 2 &oacute;r&aacute;val teljes fejf&aacute;j&aacute;smentess&eacute;get. Eredm&eacute;nyesen cs&ouml;kkentette a migr&eacute;n kís&eacute;rőt&uuml;neteit, &uacute;gymint a h&aacute;nyingert, valamint a f&eacute;ny- &eacute;s hang&eacute;rz&eacute;kenys&eacute;get. A k&eacute;szítm&eacute;nnyel kapcsolatosan &eacute;szlelt leggyakoribb mell&eacute;khat&aacute;s a h&aacute;nyinger &eacute;s a sz&eacute;d&uuml;l&eacute;s&eacute;rz&eacute;s volt, ami ar&aacute;nyaiban megegyezett a placeb&oacute;val.&nbsp;<br>A fix d&oacute;zis&uacute; szumatript&aacute;n&ndash;naprox&eacute;n-n&aacute;trium kombin&aacute;lt tabletta a migr&eacute;n akut kezel&eacute;s&eacute;ben hat&eacute;kony, j&oacute;l toler&aacute;lhat&oacute; &eacute;s biztons&aacute;gosan haszn&aacute;lhat&oacute; farmakon.</p>.
    [Abstract] [Full Text] [Related] [New Search]